On September 19, 2025, Vor Bio, listed on NASDAQ, underwent a reverse stock split at a ratio of 20 for 1. This move is often used by companies to increase the per-share price by reducing the number of shares outstanding. Vor Bio, a clinical-stage biotechnology company, focuses on developing treatments for serious autoantibody-driven conditions.
Vor Bio is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development. The company plans to present 48-week clinical data from a Phase 3 study in China, evaluating telitacicept's efficacy and safety in adults with generalized myasthenia gravis. This study is sponsored by RemeGen Co., Ltd, a collaborator listed on the Hong Kong and Shanghai Stock Exchanges.
The findings will be shared at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting in San Francisco. The presentation, titled "Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis: Results from a Phase 3 Study," is scheduled for October 29, 2025, at 10:50 am PT. This event is crucial for Vor Bio as it highlights their progress in clinical research.
Vor Bio is also participating in the Stifel 2025 Virtual Immunology and Inflammation Forum. The company will engage in a fireside chat and host virtual one-on-one investor meetings. The fireside chat is scheduled for September 15, 2025, and will be available via a live webcast on Vor Bio's website. This engagement reflects the company's commitment to investor relations and transparency.
Currently, VOR's stock is priced at $1.52, with a daily range between $1.46 and $1.585. Over the past year, the stock has fluctuated significantly, with a high of $3.29 and a low of $0.131. Vor Bio's market capitalization is approximately $192.6 million, with a trading volume of 4,701,878 shares.
